^
    2ms
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: May 2027 --> Dec 2028 | Trial primary completion date: Nov 2025 --> Jun 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    3ms
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: Feb 2028 --> May 2027
    Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    6ms
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: Apr 2027 --> Feb 2028
    Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    7ms
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Trial completion date: Jan 2028 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Oct 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    1year
    A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations. (ASCO 2023)
    We describe here the Phase 1 study of PF-07799933 as monotherapy or in combination with binimetinib or cetuximab in participants with BRAF-altered advanced solid tumors. The primary objective of Part 3 is efficacy in defined cohorts (total ~120 participants): Cohort 1-2: BRAF V600 mutant melanoma; Cohort 3: BRAF Class II altered melanoma; Cohorts 4-5: BRAF V600 and Class II altered CRC; Cohort 6: other BRAF V600, Class II/III altered solid tumor not qualifying for Cohorts 1-5. Clinical trial information: NCT05355701.
    Clinical • P1 data • PK/PD data • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF amplification
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Trial completion date: Dec 2027 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Jan 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Pfizer | Trial primary completion date: May 2026 --> Aug 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • PF-07799933
    over1year
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=174, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    2years
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=174, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933